Why Solid Biosciences Stock Is Sinking Today
Shares of Solid Biosciences (NASDAQ: SLDB) were moving 15.9% lower as of 11:29 a.m. EST on Friday. The drop came after Sarepta Therapeutics (NASDAQ: SRPT) reported disappointing clinical results for experimental gene therapy SRP-9001 in treating rare genetic disease Duchenne muscular dystrophy (DMD). Solid's leading pipeline candidate, SGT-001, is also a gene therapy targeting DMD.
Sarepta's problem was that SRP-9001 didn't meet the primary functional endpoint of its clinical study. That endpoint was a statistically significant improvement in score on the North Star Ambulatory Assessment (NSAA), a scale used to assess the functional motor abilities in children with DMD.
Image source: Getty Images.
Source Fool.com
